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The purpose of these words is to reflect upon 
the article “Transformations in the management 
of diabetes: an analysis of the scientific evidence 
published by two scientific societies (1980–2010)” 
(1) published by Salud Colectiva in late 2013.
Without a doubt a growing process of medi-
calization can be observed, one that may lead to a 
dependence associated with scientific knowledge. 
When studying the chronic disease pandemic, 
this type of disease is usually included within the 
framework of risk epidemiology, which seeks to 
establish measures of individual risk within popu-
lations. Although it has been the dominant theory 
since the 1980s, an exclusive synonymy between 
chronic disease and risk epidemiology should not 
be established. If risk were incorporated into a 
critical and sociocultural epidemiology – in which 
health is looked at from a counter-hegemonic per-
spective – concrete scenarios would be created 
that could verify this situation in a broader way 
within a critical and reflexive format. Along with 
the history of disease, the history of epidemio-
logical approaches has unfolded; the interpretation 
of the study of the history of disease in a dynamic 
and unfixed way is fundamental. Repeatedly, the 
practice of medicine across all levels of care is an 
art in which medical expertise plays a key role, 
and where sometimes the application of advanced 
technology to treat patients is required. This is the 
reason that it becomes crucial to understand in 
depth the factors that can be beneficial or harmful 
to health. Consolidating this knowledge, estab-
lishing its validity in everyday medical practice, 
is part of our professional role, given that science, 
teaching and medical practice are three essential 
elements in constituting a united and harmonic 
system within our public health system. I agree 
that the articulation of different types of method-
ology raises different problems when it comes to 
understanding their implications for practice. I also 
consider that a great amount of scientific evidence 
is part of the biomedical reductionism, which is 
why the inclusion of a critical sociocultural epi-
demiology in our approach to health problems 
is pertinent to developing a more complete and 
complex vision about health phenomena.
I am currently a member of the Argentine 
Diabetes Society (SAD) [Sociedad Argentina de 
Diabetes], an organization undergoing continuous 
growth, training and development in which ob-
stacles and challenges are not lacking. I was also a 
member of the team of authors that wrote some of 
the guidelines and recommendations published by 
SAD. I participated in some internal discussions, 
which are also part of scientific development and 
promote active participation as a social actor. It 
is not my intention to enter into concepts specifi-
cally related to diabetes, as Dr. Perner’s (1) article, 
which has inspired this text, refers to evidence 
and aspects conducive to a broader, even phylo-
anthropological reflection. 
It is my desire to clarify that the scientific 
justifications in writing recommendations, guide-
lines and consensuses are taken not only from 
randomized clinical trials, but also from long-
standing observational epidemiological studies as 
wells as experts’ knowledge and experience when 
it comes to their application and adaptation to re-
gions of our country that present diverse cultural 
characteristics. These references and justifications 
have marked and continue to mark changes in the 
history of diabetes, in its definition and its thera-
peutic application. Through basic and clinical 
investigation, other types of diabetes have been 
discovered, for example: Latent Autoimmune 
Diabetes in Adult (LADA), Maturity Onset Diabetes 
of Young (MODY), and so on, in addition to the 
most frequent types known as DM1 (Diabetes 
Mellitus, type 1), DM2 (Diabetes Mellitus, type 
2) or gestational diabetes. Knowledge of their 
existence becomes crucial, for example, when it 
comes to establishing the laboratory markers to be 
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investigated and the type of therapy that is con-
traindicated. Lack of knowledge of their existence 
and use could cause an earlier exhaustion of the 
pancreatic function in certain patients or expose 
them to acute collapse. In short, over time, the 
modification of the definition of diabetes is closely 
related not only to the type of etiology, but also 
to the type of therapeutic action that must be 
taken. It is important to highlight that in diabetes 
therapeutic conduct is not a synonym for phar-
macological application, because depending on 
the type of disease or diabetes and on the period 
of time elapsed, many times it may only signal 
hygienic-dietary and education measures. 
It is true that in Latin America and Argentina, 
the existing studies and references are too few to 
produce local indicators. It is for this very reason 
– and because Argentine technology is still im-
mersed in a changeable and inexact framework of 
safety standards – that SAD does not allow the use 
of glycosylated hemoglobin as a diagnostic test (2) 
of the disease for any type of diabetes, age group 
or biological period, as is done in other countries. 
It is not a matter of ignoring the strength of the 
knowledge available about the risk or the impor-
tance of new techniques or groups of practices to 
prevent disease, but rather a matter of cautioning 
against exaggerations in their application and of 
highlighting their relationship with aspects of per-
sonal or non-medical benefit.
Although many colleagues and referential 
figures of chronic disease frequently use the term 
pre-diabetes for patients that manifest glycemia 
out of the range considered normal and out of 
the range considered diabetes (to many a way 
of making terminology more easily understood), 
SAD insists on using the terms impaired glucose 
tolerance or impaired fasting blood glucose ac-
cording to the type of dysglycemia the patients 
manifest (2). It is not about lack of agreement, but 
about a specific point of view, an analysis and a 
reflection on the basis provided by other associa-
tions and the risk of stigmatizing patients with a 
condition that may not manifest itself, a condition 
considered treatable but not curable and that gen-
erates (unfortunately) differences and limitations in 
the patient’s social environment. In 2012, (outside 
of the publication dates of the articles analyzed 
by Dr. Perner) the American Diabetes Association 
(ADA) and the European Association for the Study 
of Diabetes (EASD) (3) published a new recom-
mendation and position in their treatment guides. 
SAD shares and implements that position, in that 
the objectives of treatment and the conduct to be 
followed should not be focused on the glycemic 
objective but rather also the characteristics, con-
ditions and history of each diabetes patient. This 
refers to the importance of a personalized medical 
conduct, which implies knowledge of the patient 
as a whole, where his/her social, economic and 
cultural situation is also taken into account. It is 
based on current scientific research, recommenda-
tions and consensus that our justifications for pro-
moting changes to a provision set forth in 1989 
and practically obsolete could be accepted (Act 
23753 was replaced by Act 26914, which is still 
not regulated, which is why this act is not in force) 
(4,5). It is based on the guidelines and recommen-
dations that we physicians who provide care can 
justify our claims regarding health care provision, 
whenever our requests for medical supplies are 
denied for patients with severe chronic conditions 
who do not have other therapeutic options and for 
whom certain treatments not recognized by the 
compulsory healthcare plan are contraindicated. 
Therefore, it is based on these recommendations 
that, when faced with extreme situations in which 
patients must take legal action and we are sum-
moned to appear at hearings as witnesses, we can 
make use of tools that serve to set legal precedents.
I agree that the tendency towards medi-
calization and the influence of the pharmaceu-
tical industry lead to many information sources 
and expert reports that exercise influence on 
the opinion, incorporation and application of 
therapies by other colleagues and promote de-
pendence on new drugs or the permanent use of 
medicines that do not even present significant or 
sufficient results regarding the use and safety stan-
dards of such drugs. It is clear that this issue entails 
complex ethical-philosophical approaches that are 
beyond the scope of this reflection. Indeed, this is 
the reason why we must educate ourselves and 
others on the basis of honest and responsible sci-
entific knowledge and its application, on the idea 
of not always treating patients pharmacologically 
and the importance of hygienic-dietary changes 
and education. It is the reason why it is important 
to educate ourselves and others in the reading and 
analysis of published scientific works, to search 
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for new publications other than those increas-
ingly influenced by the pharmaceutical industry, 
and above all, to create spaces for independent 
research and publications. 
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Firstly, I would like to thank María Amelia 
Linari for her letter (1) as a member of the 
Executive Committee of the Argentine Diabetes 
Society (SAD) [Sociedad Argentina de Diabetes], 
one of the institutions referred to in the article 
of my authorship published in Salud Colectiva 
(2). This scientific association was selected as 
an indispensable actor in the construction of the 
knowledge required to manage such a complex 
issue as diabetes, given both its history and its 
potential influence in health professionals in-
volved in diabetes management. Therefore, I 
believe that it is of great priority to engage in con-
versations that can further the discussion.
In this sense, Emma Dominguez Alonso states:
Diabetes mellitus, particularly type 2, is a 
disease whose development and evolution are 
directly related to social factors. Unhealthy 
lifestyles, lack of indispensable knowledge 
for the prevention and adequate control of 
the disease, the inaccessibility of high-quality 
health care services, among others, favor the 
development of the disease and, at the same 
time, have a negative influence on the prog-
nosis. The social origin of all of these condi-
tioning factors classify diabetes mellitus, with 
ever increasing evidence, as a social disease. 
(3 p.305)
Different studies have analyzed the social de-
terminants, showing, for instance, the impact that 
differences in body weight (as marker of the socio-
economic differences) have in the incidence of (4) 
and mortality due to type 2 diabetes (5).
